Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy

Figure 3

Results of minor variants of secondary KIT mutations of case 7 and 11 prior to therapy. Mean allele frequency of p.V654A and p.D820E substitutions for cases with and without emerging KIT exon 13 and exon 17 mutations determined by GS Junior (Roche) and MiSeq™ (Illumina) sequencing. The arrow indicates the position of the substitution.

Back to article page